cardioКардиологияKardiologiia0022-90402412-5660Kardiomag10.18087/cardio.2565cardio-259Research ArticleСтатьиСосудистые нарушения на фоне полихимиотерапии онкологических заболеванийVascular Complications of Cancer ChemotherapyБеленковЮ. Н.BelenkovYu. N.noemail@neicon.ruПриваловаЕ. В.PrivalovaE. V.noemail@neicon.ruКожевниковаМ. В.KozhevnikovaM. V.noemail@neicon.ruКириченкоЮ. Ю.KirichenkoY. Y.noemail@neicon.ruФГАОУ ВО «Первый МГМУ имени И. М. Сеченова» Минздрава РФ (Сеченовский университет)РоссияI.M. Sechenov First Moscow State Medical University (Sechenov University)Russian Federation201818112018589S49Copyright © Kardiomag, 20182018KardiomagKardiomaghttps://cardio.elpub.ru/jour/about/submissions#copyrightNoticehttps://cardio.elpub.ru/jour/article/view/259

Развитие и применение новых противоопухолевых препаратов привело к повышению выживаемости онкологических пациентов на 5 лет и более. Однако применение многих современных химиопрепаратов связано с развитием сердечно-сосудистой токсичности, что повышает риск возникновения таких заболеваний, как артериальная гипертензия, СН, тромбозы и тромбоэмболии, кардиомиопатии и аритмии. Эти побочные эффекты могут ограничивать возможности противоопухолевого лечения и снижать дальнейшие перспективы благоприятного исхода. В связи с широкой распространенностью использования современных химиопрепаратов и увеличением продолжительности жизни пациентов с онкологическими заболеваниями заболеваемость сердечно-сосудистой патологией будет продолжать расти. Соответственно необходима тщательная оценка и управление ФР развития ССЗ у онкологических больных с помощью кардиологов и онкологов, работающих вместе.

Development and use of new anticancer drugs has resulted in the improving of 5-year survival rates in patients with cancer. However, many of the modern chemotherapies are associated with cardiovascular toxicities that increases cardiovascular risk in cancer patients, including hypertension, heart failure, thrombosis and thromboembolism, cardiomyopathy, and arrhythmias. These side effects limitation restrict treatment options and farther perspectives. With increasing use of modern chemotherapies and prolongation of the cancer patients survival, the incidence of cardiovascular disease in this patient population will continue to increase. Accordingly, careful assessment and management of cardiovascular risk factors in cancer patients by oncologists and cardiologists working together is essential for optimal care.

кардиоонкологиясердечно-сосудистые заболеванияосложнения химиотерапиидисфункция эндотелиясardioangiologycardiovascular diseasescomplications of cancer chemotherapydysfunction of endotheliumReferencesFerlay J., Soerjomataram I., Dikshit R., Eser S., Mathers C., Rebelo M. et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012: Globocan 2012. International Journal of Cancer. 2015,136 (5):E359-86. DOI:10.1002/ijc. 29210Ferlay J., Soerjomataram I., Dikshit R., Eser S., Mathers C., Rebelo M. et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012: Globocan 2012. International Journal of Cancer. 2015,136 (5):E359-86. DOI:10.1002/ijc. 29210Truong J., Yan AT, Cramarossa G., Chan KKW. Chemotherapy-induced cardiotoxicity: detection, prevention, and management. Can J. Cardiol. 2014,30 (8):869-78. DOI:10.1016/j. cjca. 2014.04.029Truong J., Yan AT, Cramarossa G., Chan KKW. Chemotherapy-induced cardiotoxicity: detection, prevention, and management. Can J. Cardiol. 2014,30 (8):869-78. DOI:10.1016/j. cjca. 2014.04.029Ewer MS, Ewer S.M. Cardiotoxicity of anticancer treatments: what the cardiologist needs to know. Nature Reviews Cardiology. 2010,7 (10):564-75. DOI:10.1038/nrcardio. 2010.121Ewer MS, Ewer S.M. Cardiotoxicity of anticancer treatments: what the cardiologist needs to know. Nature Reviews Cardiology. 2010,7 (10):564-75. DOI:10.1038/nrcardio. 2010.121Suter TM, Ewer M.S. Cancer drugs and the heart: importance and management. European Heart Journal. 2013,'34 ( 15): 1102-11. D. OI: 10.1093/ eurheart j / ehs 181Suter TM, Ewer M.S. Cancer drugs and the heart: importance and management. European Heart Journal. 2013,'34 ( 15): 1102-11. D. OI: 10.1093/ eurheart j / ehs 181Bovelli D., Plataniotis G., Roila F., ESMO Guidelines Working Group. Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines. Ann Oncol. 2010,21 Suppl 5: v277-282. DOI:10.1093/annonc/mdq200Bovelli D., Plataniotis G., Roila F., ESMO Guidelines Working Group. Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines. Ann Oncol. 2010,21 Suppl 5: v277-282. DOI:10.1093/annonc/mdq200Aleman BMP, van den Belt-Dusebout AW, De Bruin ML, van't Veer MB, Baaijens MHA, Boer JP d. et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood. 2007,109 (5):1878-86. DOI:10.1182/blo od-2006-07-034405Aleman BMP, van den Belt-Dusebout AW, De Bruin ML, van't Veer MB, Baaijens MHA, Boer JP d. et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood. 2007,109 (5):1878-86. DOI:10.1182/blo od-2006-07-034405Емелина Е. И., Гендлин Г. Е., Сторожаков Г. И., Лепков С. В., Демина Е. А. Динамика показателей ЭхоКГ у больных лимфопролиферативными заболеваниями, получавших антрациклиновые препараты. Российский Медицинский Журнал. 2007, ( 1) :7-11.Емелина Е. И., Гендлин Г. Е., Сторожаков Г. И., Лепков С. В., Демина Е. А. Динамика показателей ЭхоКГ у больных лимфопролиферативными заболеваниями, получавших антрациклиновые препараты. Российский Медицинский Журнал. 2007, ( 1) :7-11.Казюлин А. Н., Вельшер Л. З., Королева И. А., Кучерявый Ю. А. К ардиотоксичность при проведении химиотерапии онкологических заболеваний. Медицина критических состояний. 2010,1 (1):62-70.Казюлин А. Н., Вельшер Л. З., Королева И. А., Кучерявый Ю. А. К ардиотоксичность при проведении химиотерапии онкологических заболеваний. Медицина критических состояний. 2010,1 (1):62-70.Daher IN, Yeh E.T. Vascular complications of selected cancer therapies. Nature Clinical Practice Cardiovascular Medicine. 2008,5 (12):797-805. DOI:10.1038/ncpcardio1375Daher IN, Yeh E.T. Vascular complications of selected cancer therapies. Nature Clinical Practice Cardiovascular Medicine. 2008,5 (12):797-805. DOI:10.1038/ncpcardio1375Epstein FH, Vane JR, Anggard EE, Botting RM. Regulatory Functions of the Vascular Endothelium. New England Journal of Medicine. 1990,323 ( 1) :27-36. DOI: 10.1056/NEJM199007053230106Epstein FH, Vane JR, Anggard EE, Botting RM. Regulatory Functions of the Vascular Endothelium. New England Journal of Medicine. 1990,323 ( 1) :27-36. DOI: 10.1056/NEJM199007053230106Soultati A., Mountzios G., Avgerinou C., Papaxoinis G., Pectasides D., Dimopoulos M-A et al. Endothelial vascular toxicity from chemotherapeu tic agents: Preclinical evidence and clinical implications. Cancer Treatment Reviews. 2012,38 (5):473-83. DOI:10.1016/j. ctrv. 2011.09.002Soultati A., Mountzios G., Avgerinou C., Papaxoinis G., Pectasides D., Dimopoulos M-A et al. Endothelial vascular toxicity from chemotherapeu tic agents: Preclinical evidence and clinical implications. Cancer Treatment Reviews. 2012,38 (5):473-83. DOI:10.1016/j. ctrv. 2011.09.002Kohli S., Kohli M. Acute Chemotherapy-Induced Cardiovascular Changes in Patients With Testicular Cancer: Are There Implications for Blood Pressure Management in Patients Receiving Chemotherapy? Journal of Clinical Oncology. 2006,24 (15):2399-2399. DOI:10.1200/JCO. 2006.05.7836Kohli S., Kohli M. Acute Chemotherapy-Induced Cardiovascular Changes in Patients With Testicular Cancer: Are There Implications for Blood Pressure Management in Patients Receiving Chemotherapy? Journal of Clinical Oncology. 2006,24 (15):2399-2399. DOI:10.1200/JCO. 2006.05.7836Meinardi MT, Gietema JA, van der Graaf WTA, van Veldhuisen DJ, Runne MA, Sluiter WJ et al. Cardiovascular Morbidity in Long-Term Survivors of Metastatic Testicular Cancer. Journal of Clinical Oncology. 2000,18 (8):1725-32. DOI:10.1200/JCO. 2000.18.8.1725Meinardi MT, Gietema JA, van der Graaf WTA, van Veldhuisen DJ, Runne MA, Sluiter WJ et al. Cardiovascular Morbidity in Long-Term Survivors of Metastatic Testicular Cancer. Journal of Clinical Oncology. 2000,18 (8):1725-32. DOI:10.1200/JCO. 2000.18.8.1725Sagstuen H., Aass N., Fossa SD, Dahl O., Klepp O., Wist EA et al. Blood Pressure and Body Mass Index in Long-Term Survivors of Testicular Cancer. Journal of Clinical Oncology. 2005,23 (22):4980-90. DOI:10.1200/JCO. 2005.06.882Sagstuen H., Aass N., Fossa SD, Dahl O., Klepp O., Wist EA et al. Blood Pressure and Body Mass Index in Long-Term Survivors of Testicular Cancer. Journal of Clinical Oncology. 2005,23 (22):4980-90. DOI:10.1200/JCO. 2005.06.882de Vos FYFL, Nuver J., Willemse PHB, van der Zee AGJ, Messerschmidt J., Burgerhof JGM et al. Long-term survivors of ovarian malignancies after cisplatin-based chemotherapy. European Journal of Cancer. 2004,40 (5):696-700. DOI:10.1016/j. ejca. 2003.11.026de Vos FYFL, Nuver J., Willemse PHB, van der Zee AGJ, Messerschmidt J., Burgerhof JGM et al. Long-term survivors of ovarian malignancies after cisplatin-based chemotherapy. European Journal of Cancer. 2004,40 (5):696-700. DOI:10.1016/j. ejca. 2003.11.026Gietema JA, Sleijfer DT, Willemse PH, Schraffordt Koops H., van Ittersum E., Verschuren WM et al. Long-term follow-up of cardiovascular risk factors in patients given chemotherapy for disseminated nonseminomatous testicular cancer. Ann Intern Med. 1992,116 (9):709-15. PMID:1558341Gietema JA, Sleijfer DT, Willemse PH, Schraffordt Koops H., van Ittersum E., Verschuren WM et al. Long-term follow-up of cardiovascular risk factors in patients given chemotherapy for disseminated nonseminomatous testicular cancer. Ann Intern Med. 1992,116 (9):709-15. PMID:1558341Strumberg D., Brügge S., Korn MW, Koeppen S., Ranft J., Scheiber G. et al. Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer. Annals of Oncology. 2002,13 (2):229-36. DOI:10.1093/annonc/mdf058Strumberg D., Brügge S., Korn MW, Koeppen S., Ranft J., Scheiber G. et al. Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer. Annals of Oncology. 2002,13 (2):229-36. DOI:10.1093/annonc/mdf058Weijl NI, Rutten MFJ, Zwinderman AH, Keizer HJ, Nooy MA, Rosendaal FR et al. Thromboembolic Events During Chemotherapy for Germ Cell Cancer: A Cohort Study and Review of the Literature. Journal of Clinical Oncology. 2000,18 (10):2169-78. DOI:10.1200/JCO. 2000.18.10.2169Weijl NI, Rutten MFJ, Zwinderman AH, Keizer HJ, Nooy MA, Rosendaal FR et al. Thromboembolic Events During Chemotherapy for Germ Cell Cancer: A Cohort Study and Review of the Literature. Journal of Clinical Oncology. 2000,18 (10):2169-78. DOI:10.1200/JCO. 2000.18.10.2169Meinardi MT, Gietema JA, van Veldhuisen DJ, van der Graaf WTA, de Vries EGE, Sleijfer D.T. Long-term chemotherapy-related cardiovascular morbidity. Cancer Treatment Reviews. 2000,26 (6):429-47. DOI:10.1053 /ctrv. 2000.0175Meinardi MT, Gietema JA, van Veldhuisen DJ, van der Graaf WTA, de Vries EGE, Sleijfer D.T. Long-term chemotherapy-related cardiovascular morbidity. Cancer Treatment Reviews. 2000,26 (6):429-47. DOI:10.1053 /ctrv. 2000.0175Role of Vascular Congestion in Cisplatin-Induced Acute Renal Failure in the Rat. Nephrology Dialysis Transplantation [Internet]. 1992 [cited 2018], DOI:10.1093/oxfordjournals. ndt. a091984Role of Vascular Congestion in Cisplatin-Induced Acute Renal Failure in the Rat. Nephrology Dialysis Transplantation [Internet]. 1992 [cited 2018], DOI:10.1093/oxfordjournals. ndt. a091984de Haas EC, Altena R., Boezen HM, Zwart N., Smit AJ, Bakker SJL et al. Early development of the metabolic syndrome after chemotherapy for testicular cancer. Annals ofOncology. 2013,24 (3):749-55. DOI:10.1093/annonc/mds527de Haas EC, Altena R., Boezen HM, Zwart N., Smit AJ, Bakker SJL et al. Early development of the metabolic syndrome after chemotherapy for testicular cancer. Annals ofOncology. 2013,24 (3):749-55. DOI:10.1093/annonc/mds527Fung C., Fossa SD, Milano MT, Sahasrabudhe DM, Peterson DR, Travis L.B. Cardiovascular Disease MortalityAfter Chemotherapy or Surgery for Testicular Nonseminoma: A Population-Based Study. Journal of Clinical Oncology. 2015,33 (28):3105-15. DOI:10.1200/JCO. 2014.60.3654Fung C., Fossa SD, Milano MT, Sahasrabudhe DM, Peterson DR, Travis L.B. Cardiovascular Disease MortalityAfter Chemotherapy or Surgery for Testicular Nonseminoma: A Population-Based Study. Journal of Clinical Oncology. 2015,33 (28):3105-15. DOI:10.1200/JCO. 2014.60.3654Lajer H., Daugaard G. Cisplatin and hypomagnesemia. Cancer Treatment Reviews. 1999,25 (1):47-58. DOI:10.1053/ctrv. 1999.0097Lajer H., Daugaard G. Cisplatin and hypomagnesemia. Cancer Treatment Reviews. 1999,25 (1):47-58. DOI:10.1053/ctrv. 1999.0097El-Awady E-SE, Moustafa YM, Abo-Elmatty DM, Radwan A. Cisplatin-induced cardiotoxicity: Mechanisms and cardioprotective strategies. EuropeanJournal of Pharmacology. 2011,650 (1):335-41. DOI:10.1016/j. ejphar. 2010.09.085El-Awady E-SE, Moustafa YM, Abo-Elmatty DM, Radwan A. Cisplatin-induced cardiotoxicity: Mechanisms and cardioprotective strategies. EuropeanJournal of Pharmacology. 2011,650 (1):335-41. DOI:10.1016/j. ejphar. 2010.09.085Rabik CA, Dolan M.E. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treatment Reviews. 2007,33 (1):9-23. DOI:10.1016/j. ctrv. 2006.09.006Rabik CA, Dolan M.E. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treatment Reviews. 2007,33 (1):9-23. DOI:10.1016/j. ctrv. 2006.09.006Yao X., Panichpisal K., Kurtzman N., Nugent K. Cisplatin Nephrotoxicity: A Review. The American Journal of the Medical Sciences. 2007,334 (2):115-24. DOI:10.1097/MAJ. 0b013e31812dfe1eYao X., Panichpisal K., Kurtzman N., Nugent K. Cisplatin Nephrotoxicity: A Review. The American Journal of the Medical Sciences. 2007,334 (2):115-24. DOI:10.1097/MAJ. 0b013e31812dfe1eMiller RP, Tadagavadi RK, Ramesh G., Reeves W.B. Mechanisms of Cisplatin Nephrotoxicity. Toxins. 2010,2 (11):2490-518. DOI:10.3390/tox-ins2112490Miller RP, Tadagavadi RK, Ramesh G., Reeves W.B. Mechanisms of Cisplatin Nephrotoxicity. Toxins. 2010,2 (11):2490-518. DOI:10.3390/tox-ins2112490Pabla N., Dong Z. Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies. Kidney International. 2008,-73 (9):994-1007. DOI:10.1038/sj. ki. 5002786Pabla N., Dong Z. Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies. Kidney International. 2008,-73 (9):994-1007. DOI:10.1038/sj. ki. 5002786Nuver J., Smit AJ, Sleijfer DT, van Gessel AI, van Roon AM, van der Meer J. et al. Microalbuminuria, decreased fibrinolysis, and inflammation as early signs of atherosclerosis in long-term survivors of disseminated testicular cancer. EuropeanJournal ofCancer. 2004,40 (5):701-6. DOI:10.1016/j. ejca. 2003.12.012Nuver J., Smit AJ, Sleijfer DT, van Gessel AI, van Roon AM, van der Meer J. et al. Microalbuminuria, decreased fibrinolysis, and inflammation as early signs of atherosclerosis in long-term survivors of disseminated testicular cancer. EuropeanJournal ofCancer. 2004,40 (5):701-6. DOI:10.1016/j. ejca. 2003.12.012Brana I., Tabernero J. Cardiotoxicity. Annals of Oncology. 2010,21 (Supplement 7):vii173-9. DOI:10.1093/annonc/mdq295Brana I., Tabernero J. Cardiotoxicity. Annals of Oncology. 2010,21 (Supplement 7):vii173-9. DOI:10.1093/annonc/mdq295Stewart T., Pavlakis N., Ward M. Cardiotoxicity with 5-fluorouracil and capecitabine: more than just vasospastic angina: Fluoropyrimidine cardiotoxicity. Internal Medicine Journal. 2010,40 (4):303-7. DOI:10.1111/j. 1445-5994.2009.02144. xStewart T., Pavlakis N., Ward M. Cardiotoxicity with 5-fluorouracil and capecitabine: more than just vasospastic angina: Fluoropyrimidine cardiotoxicity. Internal Medicine Journal. 2010,40 (4):303-7. DOI:10.1111/j. 1445-5994.2009.02144. xCwikiel M., Eskilsson J., Albertsson M., Stavenow L. The influence of 5-fluorouracil and methotrexate on vascular endothelium. An experimental study using endothelial cells in the culture. Annals of Oncology. 1996,7 (7):731-7. DOI:10.1093/oxfordjournals. annonc. a010723Cwikiel M., Eskilsson J., Albertsson M., Stavenow L. The influence of 5-fluorouracil and methotrexate on vascular endothelium. An experimental study using endothelial cells in the culture. Annals of Oncology. 1996,7 (7):731-7. DOI:10.1093/oxfordjournals. annonc. a010723Alter P., Herzum M., Soufi M., Schaefer J., Maisch B. Cardiotoxicity of 5-Fluorouracil. Cardiovascular & Hematological Agents in Medicinal Chemistry. 2006,4 (1):1-5. DOI:10.2174/187152506775268785Alter P., Herzum M., Soufi M., Schaefer J., Maisch B. Cardiotoxicity of 5-Fluorouracil. Cardiovascular & Hematological Agents in Medicinal Chemistry. 2006,4 (1):1-5. DOI:10.2174/187152506775268785Wakabayashi I., Groschner K. Vascular Actions of Anthracycline Antibiotics. Current Medicinal Chemistry. 2003,10 (5):427-36. DOI:10.2174/0929867033368259Wakabayashi I., Groschner K. Vascular Actions of Anthracycline Antibiotics. Current Medicinal Chemistry. 2003,10 (5):427-36. DOI:10.2174/0929867033368259Vejpongsa P., Yeh ETH. Prevention of Anthracycline-Induced Cardiotoxicity. Journal of the American College of Cardiology. 2014,64 (9):938-45. DOI:10.1016/j. jacc. 2014.06.1167Vejpongsa P., Yeh ETH. Prevention of Anthracycline-Induced Cardiotoxicity. Journal of the American College of Cardiology. 2014,64 (9):938-45. DOI:10.1016/j. jacc. 2014.06.1167Новаковская С. А., Арчакова Л. И. Ультраструктурная реорганизация сосудов микроциркуляторного русла миокарда при различных формах антрациклиновой кардиомиопатии. Материалы IX Международной научно-практической конференции «Дисфункция эндотелия: экспериментальные и клинические исследования», Витебск, 27 мая 2016 г [Internet]. -Витебск: ВГМУ, 2016. p. 46-8.Новаковская С. А., Арчакова Л. И. Ультраструктурная реорганизация сосудов микроциркуляторного русла миокарда при различных формах антрациклиновой кардиомиопатии. Материалы IX Международной научно-практической конференции «Дисфункция эндотелия: экспериментальные и клинические исследования», Витебск, 27 мая 2016 г [Internet]. -Витебск: ВГМУ, 2016. p. 46-8.Avelar E., Truong QA, Inyangetor D., Marfatia R., Yang C., Kaloudis E. et al. Effect of Adjuvant Chemotherapy on Left Ventricular Remodeling in Women with Newly Diagnosed Primary Breast Cancer: A Pilot Prospective Longitudinal Cardiac Magnetic Resonance Imaging Study. Journal of Thoracic Imaging. 2017,32 (6):365-9. DOI:10.1097/RTI. 0000000000000285Avelar E., Truong QA, Inyangetor D., Marfatia R., Yang C., Kaloudis E. et al. Effect of Adjuvant Chemotherapy on Left Ventricular Remodeling in Women with Newly Diagnosed Primary Breast Cancer: A Pilot Prospective Longitudinal Cardiac Magnetic Resonance Imaging Study. Journal of Thoracic Imaging. 2017,32 (6):365-9. DOI:10.1097/RTI. 0000000000000285

The authors declare that there are no conflicts of interest present.